1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca's Calquence Steps Up in First-Line CLL

Full Results Of First-Line Calquence Use In CLL

 
• By John Davis

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.

Horse_Racing
The race is on to gain market share in CLL patients • Source: Shutterstock

Initial thoughts on the full results of the ELEVATE TN study of AstraZeneca PLC’s Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), administered alone or with the anti-CD20 MAb, obinutuzumab (Roche/Genentech Inc.’s Gazyva), as first-line therapy for chronic lymphocytic leukemia, have alighted on Calquence’s favorable tolerability profile, and the intense competitive pressure likely to arise in the therapeutic segment from a number of BTK inhibitors currently in development.

Such pressures are now also expected to come from Merck & Co. Inc., which announced its intentions earlier this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

 
• By Andrew McConaghie

Its overall survival win for Datroway could be an advantage over Gilead’s Trodelvy in triple negative breast cancer.

Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment

The FDA approved the drug for combination with Roche’s Tecentriq in first-line maintenance of extensive-stage small cell lung cancer, while the NCCN added the combination to its treatment guidelines.

Attractiveness of Cell Therapy In The Spotlight With Limited Interest In Galapagos Unit

 
• By Kevin Grogan

Non-binding offers have come mostly from groups of financial investors rather than biopharma players.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.